CD20xCD3 bispecific antibodies! Roche glofitamab treatment for recurrent/refractive non-Hodgkin's lymphoma (NHL) shows strong results!

JUNE 14, 2020 /PRNewswire/ -- Roche recently released the latest data on CD20xCD3 T cells binding bispecific antibody glofitamab (formerly known as CD20-TCB) for recurrent or refractive (R)non-Hodgkin lymphoma (NHL) patients at the 25th annual meeting of the European Society of Hematology (EHA)The latest results from the Phase I Dose Increase NP30179 Study (NCT03075696) show that in patients who had previously received an over-the-top treatment with a median of three treatment options, glofitamab had a fixed course of 12 cycles (21 days/cycle) showing long-lasting total remission (CR)"Non-Hodgkin's lymphoma (NHL), such as diffuse large B-cell lymphoma (DLBCL), can present considerable treatment challenges, especially in cases involving multiple recurrences," said DrLevi Garraway, Roche's Chief Medical Officer and Global Head of Product DevelopmentWe are encouraged by these early results, which support the potential of glofitamab for patients who have previously failed multiple treatments and are in urgent need of new treatment options"Updated efficacy data from the queue of .0.6mg and s.10mg show that there is a high rate of remission in each NHL subgroup: - In the 0.6mg queue, the CR rate assessed by the researchers was 30.9% (38/123), and the total remission rate (ORR) was 45.5% (56/123)Among patients with the noble NHL, the researchers assessed a CR rate of 52.2% (12/23) and a total remission rate (ORR) of 65.2% (15/23)In the 10mg queue, the researchers assessed a CR rate of 34.1% (29/85) and a total remission rate (ORR) of 49.4% (42/85)Among patients with the noble NHL, the researchers assessed a CR rate of 50.0 percent (9/18) and a total remission rate (ORR) of 66.7 percent (12/18)CR shows persistence, with 72.7 percent (24/33) of invasive NHL patients and 81.8 percent (9/11) in inert NHL patients maintaining CR by the data deadline (April 17, 2020) in the 0.6mg queueThe median follow-up was 10.2 months, and the CR median duration in group 2 was not reachedThe security of glofitamab conforms to its mechanism of functionThe common adverse events that occurred in the queue of more than 15% of the subjects were cytokine release syndrome (CRS; n?88,56.4%), neutrophil reduction (n?48,30.8%), fever (n?47,30.1%), anemia (n-35,22.4%) and platelet reduction (n6,16.76%)Most CRS events are low -level (1-2 levels) and are related to the first cycle and are controllableGlofitamab is a research CD20xCD3 T cell that binds bispecific antibodies and is designed to target CD20 and Cd3 on the surface of B cellsThis dual-targeting activates and redirects the patient's existing T cells to eliminate target B cells by binding b cells and releasing cell venom to B cellsGlofitamab has a new "2:1" structure, designed to have two Fab sands combining CD20 and one Fab area combining CD3 Roche is currently promoting a powerful clinical development project in glofitamab to treat CD20-positive B-cell non-Hodgkin lymphoma (including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)) and other blood cancers as a single therapy and in combination with other drugs Among them, the combination of drugs, including the study of glofitamab and Polivy (polatuzumab vedotin), Tecentriq, Mab Thera/Rituximab and Gazyva/Gazynuuzumab, in the NHL and other blood cancers, involved in a variety of treatment environments and types of treatment, including early treatment, to determine the benefits of the treatment (BioValley Bioon.com) Original source: Roche ons updated data on novel CD20xCD3 bispecific cancer cancer ei dingerapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas